Search
Now showing items 1-4 of 4
Pro-inflammatory cytokine licensing as a strategy to enhance the efficacy of syngeneic mesenchymal stem cells for corneal transplantation
(NUI Galway, 2018-05-11)
It has previously been demonstrated by our lab that allogeneic MSCs prolong corneal allograft survival however syngeneic MSCs fail to do so. The aim of this study was to investigate if pre-treating syngeneic MSCs with ...
Immunomodulation in mesenchymal stem cell therapy for osteoarthritis: mechanistic insights on the role of cell death and engraftment
(NUI Galway, 2018-11-02)
Osteoarthritis (OA) is a degenerative pathology of the articular cartilage causing chronic
pain and disability in millions of individuals. In OA synovia, resident macrophages and
infiltrated lymphocytes contribute to the ...
Feasibility of mesenchmyal stem cells as modulators of inflammation and as a cellular model to study cartilage damage in osteoarthritis
(NUI Galway, 2020-04-10)
Osteoarthritis (OA) is the most common degenerative condition affecting whole joints and causing pain and cartilage degeneration, particularly in the elderly population. Inflammation of the synovium is now recognised as ...
Enhancing the immunomodulatory capacity and therapeutic potential of mesenchymal stromal cell-derived small extracellular vesicles through cytokine licensing
(NUI Galway, 2023-09-12)
The immunomodulatory capacity of mesenchymal stromal cells (MSCs) is well
established, and is being explored as a cellular therapy for the treatment of various
inflammatory-based conditions. In recent years, the role of ...